"Isotope Innovator ASP Powers $300M EBITDA Ambition with 2030 Vision"

ASP Isotopes Inc. (NASDAQ: ASPI) has announced significant milestones and strategic developments in its isotope production and commercialization efforts, positioning itself as a key player in the advanced materials sector. The company has successfully shipped its first samples of Ytterbium-176 and Silicon-28 to customers, fulfilling a crucial step in its transition from a research-focused entity to a commercial organization. These isotopes are expected to contribute up to $70 million in potential revenue over the next two years. Additionally, ASP Isotopes has begun procuring long-lead time equipment for four new laser production plants, which will start construction in Q1 2026 and are designed to enrich a variety of in-demand isotopes, including Gadolinium-160, Zinc-68, Nickel-64, and Lithium-6/7.

The company’s collaboration with Fermi America marks a transformative partnership, with plans to co-locate facilities at the HyperGrid Campus in Amarillo, Texas, near the DOE’s Pantex Plant. This joint venture aims to produce high-assay low-enriched uranium (HALEU) for the small modular reactor industry, supporting Fermi America’s ambitious goal to generate over 6 GW of nuclear power to support AI infrastructure and data centers. Quantum Leap Energy (QLE), a subsidiary of ASP Isotopes, is also preparing for a public listing in Q4 2025 and has initiated procurement for its first enrichment facility. Dr. Ryno Pretorius, appointed as QLE’s CEO in May 2025, brings extensive experience in nuclear fuel production and technology scale-up, further strengthening the company’s leadership.

ASP Isotopes has also made notable progress in its medical isotope division through PET Labs, which recently achieved full operational capacity with its second cyclotron. The facility is running at peak utilization and is expected to deliver a surge in SPECT radioisotope doses in Q4 2025. Additionally, PET Labs’ initiative to provide free treatments to children under 18 has bolstered the company’s reputation and partnerships in South Africa, enhancing its positioning for future growth. The company’s collaboration with IsoBio, which is developing targeted radiotherapeutics using isotopes such as Lutetium-177 and Actinium-225, is expected to reduce risks in the radiotherapy development pipeline and enhance the group’s competitive edge in precision oncology.

On the financial front, ASP Isotopes has expanded its management team significantly, with a focus on strengthening its C-suite and commercial leadership. Key appointments include Heather Kiessling as Group CFO, Donald Ainscow as General Counsel, and Viktor Petkov as Chief Commercial Officer, among others. These hires aim to bolster the company’s operational, legal, and financial capabilities as it scales its operations and pursues international expansion. The company also listed its shares on the Johannesburg Stock Exchange (JSE) on August 27, 2025, under the ticker ISO, with the goal of enhancing shareholder liquidity and attracting institutional investment. As of the latest data, 74.3% of the company is owned by institutional investors and insiders.

Looking ahead, ASP Isotopes has outlined a long-term financial vision to generate over $300 million in EBITDA by 2030, driven by a combination of isotope sales, helium production, and LNG contributions in the South African energy market. The company is also preparing for an analyst event in November to provide a detailed roadmap toward this target. The Renergen merger, expected to close in 3Q 2025, is anticipated to create synergies and a vertically integrated supply chain, with Renergen projected to contribute at least $20 million in revenue in 2026. These strategic moves underscore ASP Isotopes’ commitment to leveraging its proprietary Aerodynamic Separation Process to meet growing demand in healthcare, technology, and green energy sectors.

Source:

[1] ASP Isotopes Issues Letter to Shareholders (https://ir.aspisotopes.com/news-events/press-releases/detail/77/asp-isotopes-issues-letter-to-shareholders)